

**EXPORT LICENSE**

NRC FORM 250



**United States of America**  
 Nuclear Regulatory Commission  
 Washington, D.C. 20555

**NRC LICENSE NO.:** XMAT422/04

Page 1 of 13

**NRC DOCKET NO.:** 11005997

**LICENSE EXPIRES:** December 31, 2025

Pursuant to the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974 and the regulations of the Nuclear Regulatory Commission (NRC) issued pursuant thereto, and in reliance on the statements and representations herefore made by the licensee, a license is hereby issued to the licensee authorizing the export of the materials and/or production or utilization facilities listed below, subject to the terms and conditions herein.

<p align="center"><b>LICENSEE</b></p> <p>Cambridge Isotope Laboratories Inc.                  50 Frontage Road                  Andover, MA 01810</p> <p>Attn: Rebecca Dabkowski</p>	<p align="center"><b>ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)</b></p> <p align="center">See following page(s)</p>
<p align="center"><b>INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)</b></p> <p align="center">See following page(s)</p>	<p align="center"><b>OTHER U.S. PARTY(IES) TO EXPORT</b></p> <p align="center">None</p>

**APPLICANT'S REFERENCE:** Appl dated 07/29/2020

**ULTIMATE DESTINATION:** China

<b>QUANTITY(IES)</b>	<b>DESCRIPTION OF MATERIAL(S) OR FACILITY(IES)</b>
	<p>This license is amended to: 1) increase the total amount of the various deuterium compounds from 10,000 kgs to 15,000 kgs; 2) update the licensee point of contact; 3) extend the expiration date from May 31, 2024 to December 31, 2025; 4) update the lists of the Ultimate and Intermediate Consignees by adding additional parties and changing addresses; and 5) update the addresses to Other U.S. Parties to Export.</p> <p>The licensee is authorized to export a cumulative total of 15,000 kilograms of deuterium, in the form of deuterium oxide, deuterium gas, and other compounds. The cumulative total starts from the issuance of original export license XMAT422.</p> <p><b>CONDITION:</b> A license amendment request is required for the addition of intermediate consignees not listed on this export license.</p>

Neither this license nor any right under this license shall be assigned or otherwise transferred in violation of the provisions of the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974.

This license is subject to the right of recapture or control by Section 108 of the Atomic Energy Act of 1954, as amended, and to all the other provisions of said Acts, now or hereafter in effect and to all valid rules and regulations of the NRC.

**THIS LICENSE IS INVALID UNLESS SIGNED BELOW  
 BY AUTHORIZED NRC REPRESENTATIVE**

**SIGNATURE:** David Skeen  
Digitally signed by David Skeen  
 Date: 2021.09.28 09:58:09 -04'00'

**NAME AND TITLE:** David L. Skeen, Deputy Director  
 Office of International Programs

**DATE OF ISSUANCE:** September 28, 2021

**ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

1. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

2. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

3. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

4. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

5. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

6. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

7. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

8. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

**ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

9. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
10. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
11. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
12. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
13. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
14. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
15. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
16. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

**ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

17. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

18. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

19. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

20. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

21. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

22. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

23. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

24. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

**ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

25. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

26. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

27. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

28. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

29. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

30. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

31. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

32. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

**ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

33. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

34. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

35. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

36. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

37. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

38. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

39. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

40. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

**ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

41. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

42. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

43. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

44. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

45. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

46. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

47. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

48. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

**ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

49. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

50. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

51. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

52. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

53. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

54. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

55. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

56. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)



**ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

57. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
58. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
59. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
60. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
61. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
62. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
63. [REDACTED]  
China  
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

**INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

1. [REDACTED]  
China  
(for distribution to ultimate consignees)

**INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

2. [REDACTED]

China

(for distribution to ultimate consignees)

3. [REDACTED]

China

(for distribution to ultimate consignees)

4. [REDACTED]

China

(for distribution to ultimate consignees)

5. [REDACTED]

China

(for distribution to ultimate consignees)

6. [REDACTED]

China

(for distribution to ultimate consignees)

7. [REDACTED]

China

(for distribution to ultimate consignees)

8. [REDACTED]

China

(for distribution to ultimate consignees)

**INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

9. [REDACTED]  
China  
(for distribution to ultimate consignees)

10. [REDACTED]  
China  
(for distribution to ultimate consignees)

11. [REDACTED]  
China  
(for distribution to ultimate consignees)

12. [REDACTED]  
China  
(for distribution to ultimate consignees)

13. [REDACTED]  
China  
(for distribution to ultimate consignees)

14. [REDACTED]  
China  
(for distribution to ultimate consignees)

15. [REDACTED]  
China  
(for distribution to ultimate consignees)

16. [REDACTED]  
China  
(for distribution to ultimate consignees)

**INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

17. [REDACTED]

China  
(for distribution to ultimate consignees)

18. [REDACTED]

China  
(for distribution to ultimate consignees)

19. [REDACTED]

China  
(for distribution to ultimate consignees)

20. [REDACTED]

China  
(for distribution to ultimate consignees)

21. [REDACTED]

China  
(for distribution to ultimate consignees)

22. [REDACTED]

China  
(for distribution to ultimate consignees)

23. [REDACTED]

China  
(for distribution to ultimate consignees)

24. [REDACTED]

China  
(for distribution to ultimate consignees)

**INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):**

25. [REDACTED]  
China  
(for distribution to ultimate consignees)

26. [REDACTED]  
China  
(for distribution to ultimate consignees)

27. [REDACTED]  
China  
(for distribution to ultimate consignees)

28. [REDACTED]  
China  
(for distribution to ultimate consignees)

29. [REDACTED]  
China  
(for distribution to ultimate consignees)

30. [REDACTED]  
China  
(for distribution to ultimate consignees)

**OTHER U.S. PARTY(IES) TO EXPORT:**

1. Cambridge Isotope Laboratories, Inc.  
6 Highwood Drive  
Tewksbury, MA 01876  
(supplier)
2. Cambridge Isotope Separations  
1689 Burnett Drive  
Xenia, OH 45385  
(supplier)